Can Diabetics Safely Take Blood Thinners?

People with diabetes can take blood thinners, and millions do so every day. The real question is when the benefits outweigh the risks, and the answer depends heavily on what condition the blood thinner is treating, which drug is being used, and how well-controlled the diabetes is. Diabetes itself pushes the body toward forming clots more readily, which makes blood thinners genuinely valuable for many patients. But diabetes also raises the baseline risk of bleeding, creating a tighter margin between benefit and harm than in people without diabetes.

Why Diabetes Makes Clotting a Bigger Problem

The combination of insulin resistance, high blood sugar, and excess free fatty acids damages blood vessel walls, ramps up inflammation, and makes platelets stickier than normal. These changes promote the formation of blood clots and accelerate atherosclerosis, the buildup of fatty deposits in arteries.¹ The inner lining of blood vessels, the endothelium, normally produces nitric oxide to keep platelets from clumping together. In diabetes, endothelial dysfunction reduces nitric oxide output, which makes platelets more prone to activation and aggregation.² This is why heart attacks, strokes, and peripheral artery disease are so common in people with diabetes and why blood thinners come up so often in their medical care.

Aspirin for People Who Have Not Had a Heart Attack or Stroke

This is where the evidence gets genuinely tricky. For decades, many doctors routinely recommended low-dose aspirin for anyone with diabetes, assuming the cardiovascular protection would be worth the risk. A large trial called ASCEND, which followed more than 15,000 people with diabetes and no history of cardiovascular events for about seven years, tested that assumption directly. Aspirin did reduce serious vascular events like heart attacks and strokes, but it also caused more major bleeding, mainly in the gut. The absolute benefit was largely cancelled out by the bleeding hazard.³

A meta-analysis that pooled data from multiple trials offered a slightly more refined picture. When the researchers grouped patients by their underlying cardiovascular risk, aspirin reduced the chance of major cardiovascular events in people at moderate or high risk but not in those at low risk. Meanwhile, the extra bleeding showed up more clearly in the low-risk group.⁴ The practical takeaway: aspirin is not a blanket recommendation for everyone with diabetes. If your cardiovascular risk is already elevated by factors like high blood pressure, high cholesterol, smoking, or a strong family history, the math may favor aspirin. If your risk is low, the bleeding you are inviting may outweigh the clots you are preventing.

When Someone Has Already Had a Cardiovascular Event

Once a person with diabetes has had a heart attack, stroke, or other serious vascular event, the calculus shifts. The risk of another event is high enough that blood thinners provide a clearer net benefit. Both aspirin and clopidogrel (a different antiplatelet drug) are used in this setting. A meta-analysis comparing the two head-to-head in people with type 2 diabetes who had already had an ischemic stroke found no significant difference between them in preventing recurrent strokes, heart attacks, or death.⁵ Both drugs worked, and neither was dramatically safer or more effective than the other in this specific population. The choice between them often comes down to individual tolerability and other medications a person is already taking.

It is worth noting that diabetes can blunt the response to standard antiplatelet agents. The metabolic changes of insulin resistance and high blood sugar are associated with reduced effectiveness of aspirin and clopidogrel, a phenomenon sometimes called “high on-treatment platelet reactivity.”² This does not mean the drugs fail entirely, but it may explain why cardiovascular event rates remain stubbornly high in some patients with diabetes despite treatment.

Anticoagulants for Atrial Fibrillation

Atrial fibrillation, the most common serious heart rhythm disorder, dramatically raises the risk of stroke by allowing blood to pool and clot in the heart. Diabetes and atrial fibrillation frequently coexist, and when they do, anticoagulant therapy is usually essential. The question for patients with diabetes is not whether to anticoagulate but which drug to use.

Older-generation anticoagulants like warfarin have long been the standard, but newer direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran have been gaining ground. A meta-analysis of phase III randomized trials found that DOACs reduced stroke and systemic embolism compared with warfarin in people with diabetes, with no interaction between diabetes status and the drug’s benefits for ischemic stroke, major bleeding, or intracranial bleeding. The absolute reduction in vascular death was actually larger in people with diabetes than in people without it.⁶

A meta-analysis of real-world observational studies reinforced this conclusion, finding that DOACs were associated with lower risks of stroke, heart attack, major bleeding, and intracranial hemorrhage compared with warfarin in people with diabetes and atrial fibrillation.⁷ A UK retrospective study of about 8,500 patients with type 2 diabetes and atrial fibrillation told a slightly less dramatic story, finding no significant differences between DOACs and warfarin for most outcomes, though the results were consistent in the direction of DOACs being at least as safe and effective.⁸ Taken together, the evidence supports DOACs as at least comparable to warfarin for people with diabetes and atrial fibrillation, with some data suggesting they are better. DOACs also have the practical advantage of not requiring regular blood monitoring, which matters for people already managing blood sugar testing.

Peripheral Artery Disease and Combination Therapy

Peripheral artery disease, where narrowed arteries reduce blood flow to the legs and feet, is a serious and common complication of diabetes. It increases the risk of limb amputation and cardiovascular death. Standard treatment includes aspirin, but researchers have tested whether adding a low dose of the anticoagulant rivaroxaban to aspirin offers extra protection. In a large trial, the subgroup of patients with diabetes showed a significant reduction in cardiovascular death, heart attack, stroke, and major limb events when treated with rivaroxaban plus aspirin compared with aspirin alone. The absolute benefit was actually larger in people with diabetes than in those without.⁹

This combination approach is not without trade-offs. A smaller trial comparing rivaroxaban alone with low-dose aspirin in people with type 2 diabetes found that rivaroxaban improved the function of blood vessel walls but also increased bleeding events.¹⁰ Additionally, a small study of patients with diabetes, severe vascular disease, and foot ulcers found that the low-molecular-weight heparin dalteparin improved skin oxygenation and produced a less clot-prone fibrin structure, suggesting anticoagulants could even help with wound healing in severely affected limbs.¹¹ These are promising findings, though the bleeding cost of adding anticoagulants to antiplatelet therapy always needs to be carefully weighed.

The Bleeding Risk With Diabetes Alone

One fact that sometimes gets lost in these discussions: diabetes itself raises the risk of major bleeding, even without blood thinners. A large Danish study tracking thousands of bleeding events found that among people not taking aspirin, those with diabetes had roughly 60% higher rates of major bleeding compared with people without diabetes. The increase applied to both gastrointestinal and intracranial bleeding.¹²

An interesting nuance emerged when the researchers looked at people who were taking aspirin. Among aspirin users, the gap between those with and without diabetes narrowed considerably, with only a small excess risk of major bleeding in the diabetes group. The study’s authors suggested this could mean that the vascular damage diabetes causes, which raises baseline bleeding risk, overlaps mechanistically with the pathways aspirin affects. Whatever the explanation, the finding underscores that when discussing bleeding risk with blood thinners, you should factor in the elevated baseline risk that diabetes already creates, not just the additional risk the drug adds on top.¹²

Kidney Disease Changes the Equation

Many people with diabetes eventually develop some degree of kidney disease, and this matters enormously for blood thinner safety. DOACs are partly cleared by the kidneys, so as kidney function declines, drug levels in the blood rise, increasing the risk of bleeding. One analysis found that drug exposure for certain factor Xa inhibitors increased by roughly a third with mildly reduced kidney function and by about 70% or more with moderate to severe impairment.¹³

All DOACs can be used with impaired kidney function, but doses need to be adjusted based on how much kidney function remains. In end-stage kidney disease, DOACs are generally avoided altogether because there is not enough data on their safety and effectiveness in that population.¹⁴ For someone with diabetes and declining kidney function, this means regular monitoring of kidney function tests and potentially switching drugs or adjusting doses over time. Warfarin, which is metabolized by the liver rather than the kidneys, does not accumulate in the same way, but it brings its own monitoring burden through regular INR blood tests.

Drug Interactions Between Blood Thinners and Diabetes Medications

The specific diabetes medication a person takes can affect how safely they tolerate a blood thinner. The interaction that deserves the most attention involves sulfonylureas, a class of diabetes drugs that stimulate the pancreas to release more insulin. A cross-sectional study found a strong correlation between the combination of warfarin and sulfonylureas and increased bleeding risk. The same study found that aspirin combined with sulfonylureas also showed a notable correlation with bleeding, though it was weaker than the warfarin combination.¹⁵ By contrast, the combinations of warfarin or aspirin with metformin or insulin showed minimal bleeding correlations.

The mechanism is not fully understood. One possibility is that sulfonylureas and warfarin compete for the same protein-binding sites in the blood, which could raise the effective concentration of both drugs. A case report described a patient on warfarin whose blood-thinning effect became dangerously elevated after starting glibenclamide (a sulfonylurea), suggesting a direct pharmacological interaction.¹⁶ While formal clinical trials studying this interaction are lacking, the pattern has been flagged in enough databases and case reports that it warrants caution. If you take a sulfonylurea and are starting warfarin, or vice versa, more frequent monitoring of your blood-clotting levels is reasonable.

Herbal supplements add another layer of complexity. Garlic supplements can amplify the antiplatelet and anticoagulant effects of both aspirin and warfarin, increasing bleeding risk. Evening primrose oil can have similar effects, enhancing bleeding potential when combined with blood-thinning medications.¹⁷ People with diabetes sometimes turn to supplements for blood sugar management or general health, so it is important to disclose all supplements to your prescribing doctor, not just prescription medications.

How Blood Sugar Control Affects Clotting

Poorly controlled blood sugar does not just raise the long-term risk of complications — it actively makes the blood more prone to clotting in the short term. People with type 2 diabetes and chronically high blood sugar (hemoglobin A1c above 8%) tend to have platelet counts roughly 10% higher than those with well-controlled diabetes, along with larger and more active platelets.¹⁸ Even a single spike in blood sugar can trigger a more aggressive clotting and inflammatory response in blood vessels. In animal studies, restoring normal blood sugar reduced this heightened response.¹⁹

High blood sugar also makes clots harder to break down once they form. In both type 1 and type 2 diabetes, elevated glucose promotes changes to fibrin (the protein that forms the scaffold of clots) that make clots denser and more resistant to the body’s natural clot-dissolving system.²⁰ This means that good glycemic control is not just generally healthy; it directly affects how well blood thinners can do their job. A blood thinner working against a background of chronically high blood sugar is fighting an uphill battle against platelets that are more active and clots that are more stubborn.

Eye Health and Blood Thinners

One concern specific to people with diabetes is diabetic retinopathy, the eye disease caused by damage to tiny blood vessels in the retina. Patients and doctors sometimes worry that blood thinners could increase the risk of bleeding in the eye. A study of patients with acute posterior vitreous detachment found that those taking aspirin, clopidogrel, or warfarin had a higher rate of vitreous hemorrhage (bleeding inside the eye) compared with those not on these medications.²¹ While this study was not specific to diabetes, people with diabetic retinopathy already have fragile retinal blood vessels, so the added risk of blood thinners in the eyes is a legitimate consideration. It does not mean blood thinners are off the table, but it does mean the eye should be part of the conversation when weighing risks and benefits, particularly for people with proliferative diabetic retinopathy or a history of vitreous hemorrhage.

Predicting Who Will Bleed and Who Will Benefit

Standard clinical scoring systems, like HAS-BLED for bleeding risk and CHA₂DS₂-VASc for stroke risk, are used widely in people taking blood thinners. But these tools were not designed specifically for people with diabetes, and researchers have been working on alternatives. A study developed new scoring models specifically for predicting bleeding and ischemic events in patients with diabetes taking ticagrelor (a potent antiplatelet drug). The new models outperformed the standard scores in this population.²² These tools are not yet in widespread clinical use, but they reflect growing recognition that people with diabetes have a distinct risk profile that generic scoring systems do not fully capture.

Factor XI Inhibitors on the Horizon

One of the most interesting developments in anticoagulation research is the emergence of drugs that target factor XI, a clotting protein that sits at a juncture in the coagulation cascade where it contributes to pathological clotting but appears less critical for the kind of clotting that stops wounds from bleeding. Elevated levels of factor XI have been linked to an increased risk of cardiovascular events specifically in people with type 2 diabetes, making this target particularly relevant to this population.²³ The hope is that these drugs could prevent dangerous clots while causing far less bleeding than current blood thinners. Several factor XI inhibitors are in clinical trials, and if they deliver on this promise, they could substantially reshape the risk-benefit conversation for people with diabetes who need anticoagulation.

Surgery and Temporary Stops

People with diabetes who take blood thinners face a particular challenge around surgical procedures. Blood thinners usually need to be stopped before surgery to prevent excessive bleeding, but stopping them creates a window where the patient is unprotected against clots. For people with diabetes, who already have an elevated clotting tendency, this window can be riskier than for the general population. Current perioperative guidelines address how to manage the timing of stopping and restarting various anticoagulants and antiplatelet drugs around surgery, and these guidelines also account for the need to maintain glycemic control during the perioperative period, since blood sugar tends to swing during the stress of surgery. The key point for patients is that this requires coordinated planning between the surgeon, the prescribing physician, and sometimes an anesthesiologist, not a unilateral decision to stop taking a medication.